Feb 21, 2020
Got #crmd, it was delicious (at CRMD) https://www.instagram.com/p/B80Wl41pucM/?igshid=1r7pedd5zc2oa
Loading...
seen from Latvia
seen from Yemen
seen from United States
seen from United States
seen from Poland
seen from United States
seen from United States
seen from United States
seen from United States
seen from Ecuador
seen from United States
seen from United States
seen from United States
seen from United States
seen from Romania
seen from China
seen from Netherlands
seen from United States
seen from Türkiye
seen from United States
Got #crmd, it was delicious (at CRMD) https://www.instagram.com/p/B80Wl41pucM/?igshid=1r7pedd5zc2oa
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot
CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot
— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year.
— Net sales dropped to $59.53 million from $372.5 million in the same period of last year
— Net loss before recognition of the deemed dividends was $5.3 million
— Operating…
View On WordPress
CorMedix falls ahead of Q1 results; reporting after the bell today
CorMedix falls ahead of Q1 results; reporting after the bell today
Biopharmaceutical company CorMedix (CRMD) is set to report its first quarter 2019 results after the bell today. CorMedix stock had dropped about 4% at 3:00 PM ET. Market watchers expect the company to post a loss of 28 cents per share on revenue of $60,000 for the recently ended quarter.
CorMedix, which develops and commercializes therapeutic products for the prevention and treatment of…
View On WordPress
Q4 Earnings Preview: All eyes on Neutrolin trial updates from CorMedix
Q4 Earnings Preview: All eyes on Neutrolin trial updates from CorMedix
Biopharma firm CorMedix (NYSE American: CRMD) has seen its shares skyrocket more than 500% in the last 12 months as investors are pinning their hopes on the positive LOCK trial results. Investors would be interested to know from the management how the ongoing discussions with the FDA regarding the phase 3 trial results and future course of action.
CorMedix is planning to report its fourth-quarter…
View On WordPress
#crmamemorablenight #crmd #crmp #crmhb #crmj #crm80 #crmovement #crmoments #crmodas #crma #vemcrm #crmjewelers #crm50 #crmr #crmusiclivemusic #crm #crm250ar #prilaga #crm250 #crmday #crmo #crmv #crmvrn #crmoto #crmotos #amocrm #crmarch #crmatheprinzessinnight #crmc #crmagazine #crms https://www.instagram.com/p/Bu8CjE7A6pb/?utm_source=ig_tumblr_share&igshid=4jjbdkp086oc
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
CorMedix Inc. (NYSE:CRMD) Has Analysts Optimistic
CorMedix Inc. (NYSE:CRMD) Has Analysts Optimistic
CorMedix Inc. (NYSE:CRMD)
December 6th, 2018 CorMedix Inc. finished up $0.31 Thursday, a 23.13% increase, closing at $1.65. The stock continues to trade well at 871% of its 52 week low of $0.17. In addition to finishing higher, trading volumes were solid at 316% of normal which can indicate investors see opportunities. Be aware that the Altman Z-Score1 (An indicator of the probability for a…
View On WordPress
(NYSE:CRMD) CorMedix Inc. Analysts Are Taking A Positive Outlook
(NYSE:CRMD) CorMedix Inc. Analysts Are Taking A Positive Outlook
CorMedix Inc. (NYSE:CRMD)
November 19th, 2018 Amidst falling markets CorMedix Inc. closed Monday up 21.98%, a $0.22 increase to close on $1.20. The stock continues to trade well at 606% of its 52 week low of $0.17. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the recommended threshold of 1.8%, and calculated to be -56.18. (more…)
View On WordPress
PEDEVCO (PED:ASE) and Cormedix (CRMD:ASE) Are Biggest Stock Gainers YTD on AMEX
PEDEVCO (PED:ASE) and Cormedix (CRMD:ASE) Are Biggest Stock Gainers YTD on AMEX
Stockcalc – Free Trial
Have a free look inside the StockCalc website at www.stockcalc.com
I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.
Biggest Stock Gainers Year to Date on AMEX
Today we are looking at companies that have had the greatest…
View On WordPress